Size should form the scientific basis for defining nanomaterials, says EU panel
This article was originally published in SRA
Executive Summary
The European Commission's Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) believes that the size of a material or its constituent parts – and not its physical or chemical properties – should form the scientific basis for deciding whether it qualifies as a nanomaterial1.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.